Uveal meatstatic melanoma – pro
Pelster et al reported a phase 2 study of this combination and metastatic Mobile melanoma which showed a partial response of 17% with 53% showing stable disease. Similarly, Rodriguez et al presented an additional phase 2 singlearm study of this combination in patients with uveal melanoma which resulted in 12% overall response rate with 52% disease stabilization rate. The current National Comprehensive Cancer Network Guidelines Melanoma 1.2019 considers the use of this combination as systemic therapy for uveal melanoma to be a category 2A recommendation, which indicate uniform consensus.
Meredith Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, …Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 9522-9522.
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018;10:1758834018757175.
Vidhya Karivedu et al, Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Case Reports in Oncological Medicine
Volume 2019, Article ID 3560640, 8 pages
Namikawa K et al, Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.Melanoma Res. 2019 May 14.